The disclosure is directed to medroxyprogesterone compositions suitable for subcutaneous injection comprising about 360 mg/ml to 440 mg/ml or about 160 mg/ml to 240 mg/ml medroxyprogesterone acetate, 1.7 mg/ml to 2.3 mg/ml docusate sodium, polyethylene glycol, and water. Methods of using these compositions are also described.